Non-Canonical WNT/Wnt5a Pathway Activity in Circulating Monocytes of Untreated Psoriatic Patients: An Exploratory Study of Its Association with Inflammatory Cytokines and Cardiovascular Risk Marker-ADAMTS7.
WNT5a
cardiovascular risk
inflammation
monocytes
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
21
12
2022
revised:
03
02
2023
accepted:
04
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
The leading cause of death in psoriasis is cardiovascular disease. The determinants that induce the increase in this risk are not known. The systemic inflammatory process is dependent on lymphocytes and monocytes, as has been proposed. However, adaptation modules such as mTOR have recently been mentioned as having a role. Other factors, such as WNT and its non-canonical WNT5a-inducing pathway, are relevant in inflammation, cell migration, and neoangiogenesis. Thus, we studied circulating monocytes from untreated severe psoriatic patients and characterized inflammatory cytokines, chemokines, mTOR activity, and the cardiovascular risk marker ADAMTS7. Peripheral blood from ten severely psoriatic patients (Psoriasis severity index greater than 10) was extracted and age- and sex-matched with healthy subjects. Surface and intracellular flow cytometry were performed for cytokine, chemokine receptors, and mTOR activity. ADAMTS7 was measured using ELISA. Psoriatic patients had a higher frequency of WNT5a+ cells in monocytes, which also had higher levels of IL-1β, IL-6, CXCR3, CCR2, and phosphorylated S6R protein. We found that M1 monocytes are dominant in the WNT5a+ cell group, and intracellular levels of WNT5a were also augmented. Levels of WNT5a were correlated with ADAMTS7, a blood marker related to the pathogenesis of atheromatosis. WNT5a could be relevant to the cardiovascular risk of psoriatic patients considering its association with higher levels of inflammatory cytokines, chemokine receptors and the pro-atherogenic profile of circulating monocytes.
Identifiants
pubmed: 36831113
pii: biomedicines11020577
doi: 10.3390/biomedicines11020577
pmc: PMC9953432
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Cardiovasc Med. 2022 Mar 25;9:829709
pubmed: 35402553
Front Oncol. 2022 May 30;12:880552
pubmed: 35712511
Nat Rev Cardiol. 2015 Jan;12(1):10-7
pubmed: 25367649
J Cell Mol Med. 2019 Sep;23(9):5876-5883
pubmed: 31313518
Metabolites. 2023 Jan 11;13(1):
pubmed: 36677041
Sci Adv. 2022 Apr 22;8(16):eabl4602
pubmed: 35452290
Vasc Health Risk Manag. 2022 Feb 16;18:43-53
pubmed: 35210782
Biomolecules. 2022 Mar 15;12(3):
pubmed: 35327645
J Invest Surg. 2022 Mar;35(3):598-604
pubmed: 33818249
Eur J Prev Cardiol. 2022 Mar 30;29(4):588-590
pubmed: 33624007
JAMA. 2022 May 17;327(19):1936
pubmed: 35579640
J Am Coll Cardiol. 2021 Apr 6;77(13):1670-1680
pubmed: 33795041
Front Immunol. 2020 Oct 15;11:555245
pubmed: 33178184